Furthermore, elevated IGF2BP2 expression in primary tumor tissue was significantly linked to resistance against multiple therapies, including selumetinib, gefitinib, and regorafenib in patient-derived organoids (PDOs), as well as 5-fluorouracil and oxaliplatin [53]. The gene discussed is IGF2BP2; the disease is neoplasm.